高齢者における認知状態のグラフェン遠赤外線介入研究
This study was a 4-week facility-level cluster-controlled trial examining whether a graphene-based far-infrared intervention could improve cognitive status among older adults living in long-term care facilities. Five facilities were assigned to one of three study conditions: a graphene-based far-infrared intervention (GFII), a thermal-effects control (TEC) delivered using an electrically heated cap at the same nominal temperature, or a blank control condition without intervention. Participants in the GFII and TEC groups received one 40-minute session daily for 4 weeks. Cognitive outcomes were assessed at baseline, after approximately 2 and 4 weeks of intervention, and at a 4-week post-intervention follow-up. Depressive and anxiety symptoms were also assessed as exploratory outcomes, although they were not the primary focus of the study. The study aimed to examine whether GFII could improve cognitive status beyond the effects of thermal stimulation alone or no intervention.
調査の概要
状態
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100101
- Institute of Psychology, Chinese Academy of Sciences
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 55 years or older
- Residing in one of the participating long-term care facilities
- Able to communicate in daily life
- Willing to participate in the assigned study procedures and repeated assessments
Exclusion Criteria:
- Reporting no subjective cognitive decline on any item of the subjective cognitive decline questionnaire
- Having a medical condition that precluded localized head heating
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Graphene far infrared intervention group
Participants received a graphene-based far-infrared intervention (GFII) using a wearable cap set to a nominal temperature of 40°C. Trained caregivers assisted participants with one 40-minute session daily for 4 weeks of active intervention. Participants could sit, lie down, or undertake routine activities during each session. |
The GFII was delivered using a custom wearable cap comprising a flexible cap body with graphene-coated elements, a temperature controller, and an external power adapter. The cap covered the frontal, temporal, and occipital scalp regions and emitted far-infrared radiation primarily within the 4-14 μm range. The device was operated at a nominal temperature of 40°C. Participants received one 40-minute session daily for 4 weeks of active intervention under the assistance and supervision of trained caregivers.
他の名前:
|
|
アクティブコンパレータ:Thermal-Effects Control Group
Participants received conventional electrical heating using a commercially available heated cap set to the same nominal temperature of 40°C. The intervention followed the same schedule, 40-minute session duration, and caregiver-assistance procedures as the GFII condition. |
The thermal-effects control was delivered using a commercially available electrically heated cap without graphene-based far-infrared-emitting elements. The cap was operated at the same nominal temperature of 40°C and followed the same intervention schedule, 40-minute session duration, and caregiver-assistance procedures as the GFII condition.
他の名前:
|
|
介入なし:Blank Control Group
Participants received no cap-based intervention and continued their usual daily routines during the study period. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Subjective Cognitive Decline (SCD) Score
時間枠:Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Subjective cognitive decline was assessed using a 10-item multidomain, example-assisted questionnaire. Participants rated perceived cognitive change relative to 1-2 years earlier on a three-point scale ranging from 1 (no decline) to 3 (obvious decline). Total scores range from 10 to 30, with higher scores indicating greater subjective cognitive decline. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
|
Mini-Montreal Cognitive Assessment (Mini-MoCA) Score
時間枠:Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Objective cognitive performance was assessed using the Mini-Montreal Cognitive Assessment (Mini-MoCA), which evaluates visuospatial and executive function, attention, language, abstraction, delayed recall, and orientation. Raw scores range from 0 to 17. Following the scoring instructions, one point was added for participants with fewer than 12 years of education, yielding an education-adjusted score range of 0 to 18. Higher scores indicate better cognitive performance. Scores were analyzed continuously and were not used for clinical diagnosis. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient Health Questionnaire-9 (PHQ-9) Score
時間枠:Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Depressive symptoms were assessed using the nine-item Patient Health Questionnaire (PHQ-9). Each item is scored from 0 (not at all) to 3 (nearly every day) based on the frequency of depressive symptoms during the preceding 2 weeks. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. Scores of 10 or higher indicate clinically relevant depressive symptoms. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
|
Generalized Anxiety Disorder-7 (GAD-7) Score
時間枠:Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
Anxiety symptoms were assessed using the Chinese version of the seven-item Generalized Anxiety Disorder scale (GAD-7). Each item is scored from 0 (not at all) to 3 (nearly every day) based on the frequency of anxiety symptoms during the preceding 2 weeks. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. Scores of 10 or higher indicate clinically relevant anxiety symptoms. |
Baseline (T1), after approximately 2 weeks of active intervention (T2), after completion of 4 weeks of active intervention (T3), and approximately 4 weeks after T3 (T4)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 2023YFC3605304-1
- 2023YFC3605304 (その他の助成金/資金番号:National Key Research and Development projects)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified participant-level clinical outcome data underlying the findings reported in the publication will be available from the corresponding author upon reasonable request. Access to biomarker data will be considered separately, subject to ethical approval, data-use agreements, and applicable privacy requirements. Potentially identifying information will be withheld or minimized to protect participant privacy.
IPD 共有時間枠
Beginning at publication and continuing for 3 years thereafter.
IPD 共有アクセス基準
Data will be considered for sharing with qualified researchers for noncommercial research purposes, including verification of the reported findings. Requests must include an appropriate research proposal and will be subject to applicable ethical and institutional requirements and a data-use agreement. Requests should be directed to the corresponding author.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。